On the back of Sandoz’s FDA approval for the first-ever natalizumab biosimilar, branded as Tyruko, Biogen now has a formidable multiple sclerosis market competitor for its top-selling monoclonal antibody Tysabri.
Keren Haruvi “Tyruko has the potential to extend the reach of natalizumab treatment for these…
Click here to view original post
